Senseonics Holdings (NYSE:SENS) and Insulet (NASDAQ:PODD) are two healthcare stocks that have the potential to outpace the broader markets over the long term. The two companies are part of a rapidly expanding market, allowing them to grow revenue and improve earnings in the process. But which between the two diabetes stocks should you buy today?.A research report from the World Health Organization estimates worldwide diabetes cases at 422 million while the annual death count stands at 1.6 million. And it’s estimated that by 2045, 700 million people will suffer from this challenging disease.
The diabetes market size is projected to reach $2.8 billion by 2026. Therefore, it’s no surprise that companies that work on developing technology that treat diabetes are receiving attention from long-term investors.
In this article I analyze two diabetes companies, Senseonics Holdings Inc . (SENS) and Insulet Corp . (PODD), to see which of their stocks is currently a better buy.